XYL

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Xylem Inc. (NYSE:XYL) is not as good as DuPont de Nemours, Inc. (NYSE:DD).

Xylem cut its full-year 2026 adjusted EPS outlook by as much as $0.25 per share on October 27, 2026, citing project delays and cautious customer spending. Levi & Korsinsky is investigating potential securities law claims on behalf of XYL investors who suffered losses.

Xylem experienced a ~15% post-earnings selloff due to smart metering segment delays, but I view this as a temporary setback. XYL's integrated water solutions, utility exposure, and mission-critical equipment provide a defensive business profile, though its economic moat is narrow. Portfolio restructuring, including divestitures and segment realignment, aims to enhance growth and margins, with proceeds targeted for higher-growth acquisitions in 2027-2028.

LOS ANGELES--(BUSINESS WIRE)---- $XYL--XYL Investors Have Opportunity to Join Xylem Inc. Fraud Investigation with SBS Law.

Xylem's new 2026 adjusted EPS ceiling of $5.45 now sits below the $5.55 floor it replaced. An investigation into potential securities law violations is reviewing losses suffered by XYL shareholders Xylem's new 2026 adjusted EPS ceiling of $5.45 now sits below the $5.55 floor it replaced. An investigation into potential securities law violations is reviewing losses suffered by XYL shareholders

Xylem's Q3 earnings miss estimates as metering pressures and project timing weighed on sales, prompting it to lower its 2026 revenue and EPS outlook.

While the top- and bottom-line numbers for Xylem (XYL) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Xylem (XYL) came out with quarterly earnings of $1.44 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.37 per share a year ago.

XYL gears up for Q3 earnings, with infrastructure demand, data-center growth and the TriOS buyout likely to aid results, while rising costs pose challenges.

Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.